New and emerging data for CDK4/6 inhibitors in patients with HR+/HER2- early breast cancer
CDK4/6 inhibitors in patients with HR+/HER2- advanced breast cancer
Emerging data on outcomes for patients with cancer during the COVID-19 pandemic
Video Player Controls:
Martine J Piccart considers the latest data on the management of patients with breast cancer from the ESMO Virtual Congress 2020.
Catherine M Kelly considers the latest data on the management of patients with breast cancer from the ESMO Virtual Congress 2020.
Valentina Guarneri considers the latest data on the management of patients with breast cancer from the ESMO Virtual Congress 2020.
Please Select A Video:
Overview & Learning Objectives
In this activity, Dr Catherine M Kelly interprets the latest data on the management of patients with HR+/HER2- breast cancer from ESMO 2020.
This activity has been jointly provided by USF Health and touchIME.
This activity is intended for oncologists and breast cancer specialists involved in the management of patients with breast cancer. read more
USF Health adheres to ACCME Standards regarding commercial support of continuing medical education. It is the policy of USF Health that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that faculty will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.
Dr Catherine M Kelly discloses: Advisory Board fees from Novartis, Pfizer and Roche.
Prof. Valentina Guarneri discloses: Advisory Board fees from Eli Lilly, MSD, Novartis and Roche; Speaker Bureau fees from Eli Lilly and Novartis.
Prof. Martine J Piccart discloses: Board Membership (Scientific) for Oncolytics; Consultancy fees from AstraZeneca, Camel-IDS, Crescendo Biologics, Debiopharm, G1 Therapeutics, Roche-Genentech, Huya Bioscience International, Immunomedics, Eli Lilly, Menarini, MSD, Novartis, Odonate, PeriphaGen, Pfizer, Roche and Seattle Genetics; Institute research grants from AstraZeneca, Eli Lilly, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier and Synthon.
Ryan Bookout, PharmD, BCOP, has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Alison Scott, PhD, has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity participants must review and complete the post-test evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Advanced Practice Providers
Physician Assistants may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 9 December 2020. Date credits expire: 9 December 2021.
If you have any questions regarding credit please contact email@example.com
After watching this activity, participants should be better able to:
- Apply new and emerging data for CDK4/6 inhibitors in patients with HR+/HER2- early breast cancer in clinical practice
- Use the latest results for CDK4/6 inhibitors in patients with HR+/HER2- advanced breast cancer to inform treatment decisions in clinical practice
- Review emerging real-world data on the outcome of patients with active or a history of cancer who have developed COVID-19 during the COVID-19 pandemic